ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

All Content

This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.

There is currently not enough evidence to assess the balance of benefits and harms of a visual skin examination by a clinician to screen for skin cancer in asymptomatic adults.

Patients with RCC had greater postsurgical decreases in kidney function compared with patients with upper tract urothelial carcinoma.

Robot-assisted and open radical surgeries for prostate cancer have similar outcomes for patients at 3 months, according to clinical trial results.

In this interview we discuss a recent study that identified genetic mechanisms of immunoresistance to treatment with anti-PD-1 antibodies.

A 47-year-old man presents with a cough and dyspnea. A bronchial mass in found, and a biopsy is performed. What is your diagnosis?

Ten percent of advanced cancer patients have developed delirium, but it is often missed by emergency department physicians.

A 43-year-old woman presents with abdominal pain. Imaging detects a mass in the pancreas, and a biopsy is performed. What is your diagnosis?

A phase I trial of selinexor found the drug was reasonably well tolerated and showed some activity in patients with advanced soft-tissue or bone sarcoma with progressive disease.

New NCCN guidelines regarding genomic profiling will likely yield important opportunities to improve the care of patients with advanced bladder cancer.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.